Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230030/S012

FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARAWAVE NAV Pulsed Field Ablation C

Farapulse, Inc. · Decision date Jan 12, 2026

FDA DECISIONP230030/S012

What did the FDA approve?

FDA records P230030/S012 as a supplement to PMA P230030, with the supplement type “Panel Track”. The recorded decision is approval, dated Jan 12, 2026.

FDA approval order statement

for the FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARAWAVE NAV Pulsed Field Ablation Catheter, FARAPOINT Pulsed Field Ablation Catheter, FARASTAR Catheter Connection Cable, FARASTAR Pulsed Field Ablation Generator, FARASTAR Recording System Module, FARASTAR Mapping System Module, FARASTAR Stimulation Module Cable, FARASTAR EGM Cable, FARASTAR Stimulation Module Male Cable, FARASTAR Stimulation Module Female Cable, FARASTAR Stimulation Module Y-Cable Long, FARASTAR Stimulation Module Y-Cable Short, FARASTAR Recording System Module Catheter Pin Cable, FARASTAR Recording System Module ECG Trunk Cable, FARASTAR Recording System Module ECG Output Module (AAMI/IEC), FARASTAR Recording System Module EGM Input Module, FARASTAR SNAP CABLE R/L (AAMI/IEC), FARASTAR SNAP CABLE V SET (AAMI), FARASTAR SNAP CABLE C SET (IEC), FARASTAR Recording System Module ECG Output to Rhythmia HDx ECG Input Cable, FARASTAR Recording System Module EGM Output to Rhythmia HDx EGM Input Cable, FARASTAR Mapping System Module Back Patch Cable, FARASTAR Mapping System Module Back Patch Cable Male, FARASTAR Mapping System Module BNC BNC-Phono Cable, FARASTAR Mapping System Module Rhythmia ABL Cable, FARASTAR Mapping System Module Auxiliary Cable, FARASTAR EGM to EP Recording System Cable FARAPOINT) to add the FARAPOINT Pulsed Field Ablation Catheter and the FARASTAR EGM to EP Recording System Cable. This device is indicated for:FARAWAVE and FARAWAVE NAV Pulsed Field Ablation CathetersThe FARAWAVE Catheter is indicated for: the isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic Paroxysmal Atrial Fibrillation (PAF). the isolation of pulmonary veins and the posterior wall in the treatment of drug-refractory, symptomatic Persistent Atrial Fibrillation (episode duration less than one year).FARAPOINT Pulsed Field Ablation CatheterThe FARAPOINT Catheter is indicated for use as an adjunctive device for the creation of an ablation line between the inferior vena cava and the tricuspid valve when any FARAWAVE Catheter is used in the endocardial treatment of drug resistant, symptomatic persistent atrial fibrillation (episode duration no greater than 12 months).FARASTAR Pulsed Field Ablation GeneratorThe FARASTAR PFA Generator is intended for use with a compatible Boston Scientific PFA catheter in cardiac ablation procedures.FARASTAR Recording System ModuleThe FARASTAR Recording System Module (RSM) is indicated for use in an electrophysiology lab environment, as a filtering/protection unit to be connected between the patient and any attached recording systems and/or ECG systems, and as an interface for cardiac stimulation output.FARASTAR Catheter Connection CableThe FARASTAR Connection Cable is intended to be used with a FARAPULSE Catheter during an Electrophysiology procedure for cardiac tissue ablation.
Regulatory pathway
PMA supplement
Supplement type
Panel Track
Clinical specialty
Cardiovascular
Decision date
Jan 12, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P230030/S012
Regulatory pathway
PMA supplement
Product code
QZI
Decision code
APPR
Decision date
Jan 12, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.

Product code
QZI
FDA device class
3

For the original device and its historical approval scope, see PMA P230030. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P230030 · Original PMA

    FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARASTAR Catheter Connection Cable,

  2. P230030/S012 received

    Application receipt date recorded by FDA.

  3. P230030/S015 · Related supplement

    FARAPULSE Pulsed Field Ablation System

  4. P230030/S014 · Related supplement

    FARAPULSE Pulsed Field Ablation System

  5. P230030/S013 · Related supplement

    FARASTAR Pulsed Field Ablation (PFA) Generator; FARASTAR Mapping System Module (MSM); FARASTAR Recording System Modul

  6. P230030/S012 · FDA decision

    Panel Track

  7. P230030/S017 · Related supplement

    FARAPULSE Pulsed Field Ablation System (FARAPULSE)

  8. P230030/S019 · Related supplement

    FARAPULSE Pulsed Field Ablation System

  9. P230030/S021 · Related supplement

    FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARASTAR Catheter Connection Cable,

  10. P230030/S023 · Related supplement

    FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARASTAR Catheter Connection Cable,

  11. P230030/S022 · Related supplement

    FARAPULSE Pulsed Field Ablation System (FARAPULSE)

  12. P230030/S018 · Related supplement

    FARAPULSE Pulsed Field Ablation System

  13. P230030/S016 · Related supplement

    FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARASTAR Catheter Connection Cable,

  14. P230030/S024 · Related supplement

    FARASTAR Pulsed Field Ablation (PFA) Generator; FARASTAR Mapping System Module (MSM); FARASTAR Recording System Modul

  15. P230030/S025 · Related supplement

    FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARASTAR Catheter Connection Cable,

Timeline entries are records held by MedtechLedger for P230030. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230030

Product / regulatory recordCompanyPathwayDecision dateSource
Farapulse, Inc.PMA approvalJan 30, 2024FDA
Farapulse, Inc.PMA supplementAug 12, 2025FDA
Farapulse, Inc.PMA supplementAug 14, 2025FDA
Farapulse, Inc.PMA supplementSep 24, 2025FDA
Farapulse, Inc.PMA supplementJan 13, 2026FDA
Farapulse, Inc.PMA supplementMay 6, 2026FDA
Farapulse, Inc.PMA supplementJun 5, 2026FDA
Farapulse, Inc.PMA supplementJun 26, 2026FDA
Farapulse, Inc.PMA supplementJul 10, 2026FDA
Farapulse, Inc.PMA supplementAug 6, 2026FDA
Farapulse, Inc.PMA supplementAug 25, 2026FDA
Farapulse, Inc.PMA supplementSep 4, 2026FDA
Farapulse, Inc.PMA supplementOct 2, 2026FDA

Explore the linked device profile

Other records with product code QZI

Product / regulatory recordCompanyPathwayDecision dateSource
Biosense Webster, Inc.PMA supplementNov 3, 2026FDA
Kardium, Inc.PMA supplementOct 27, 2026FDA
Kardium, Inc.PMA supplementOct 23, 2026FDA
Volt PFA SystemP250022/S002
ABBOTT MEDICALPMA supplementOct 15, 2026FDA
Medtronic, Inc.PMA supplementOct 9, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Farapulse, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
3715 Haven Ave., Suite 110, Menlo Park, CA, 94025

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records